Recursion Pharmaceuticals (NASDAQ:RXRX) Now Covered by Morgan Stanley

Morgan Stanley assumed coverage on shares of Recursion Pharmaceuticals (NASDAQ:RXRX - Free Report) in a report released on Thursday, MarketBeat reports. The brokerage issued an equal weight rating and a $5.00 price target on the stock.

Separately, Needham & Company LLC decreased their target price on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $7.00.

Recursion Pharmaceuticals Price Performance

RXRX traded up $0.05 during trading on Thursday, hitting $5.26. The company's stock had a trading volume of 16,582,108 shares, compared to its average volume of 16,022,744. The firm has a market capitalization of $2.14 billion, a price-to-earnings ratio of -2.97 and a beta of 0.91. The business's fifty day simple moving average is $4.84 and its 200 day simple moving average is $6.11. Recursion Pharmaceuticals has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a current ratio of 4.11, a quick ratio of 4.11 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The firm had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The business's revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.39) EPS. On average, equities research analysts forecast that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers raised its position in Recursion Pharmaceuticals by 7.5% in the first quarter. Rhumbline Advisers now owns 359,175 shares of the company's stock valued at $1,900,000 after purchasing an additional 25,143 shares during the period. Focus Partners Wealth acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter valued at $77,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Recursion Pharmaceuticals by 183.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company's stock valued at $33,901,000 after buying an additional 4,149,346 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Recursion Pharmaceuticals by 7.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company's stock valued at $953,000 after buying an additional 12,372 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter valued at $890,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.